Acotiamide

Acotiamide
Clinical data
Trade names	Acofide (JP)
Routes of; administration	By mouth (tablets)
ATC code	None;
Legal status
Legal status	Rx-only (JP);
Pharmacokinetic data
Protein binding	84.21–85.95%
Metabolism	UGT1A8 and 1A9 (major)
Elimination half-life	10.9–21.7 hours
Excretion	Feces (92.7%), urine (5.3%)[1]
Identifiers
	IUPAC name N-{2-[bis(1-Methylethyl)amino]ethyl}-2-{[(2-hydroxy-4,5-dimethoxyphenyl)carbonyl]amino}-1,3-thiazole-4-carboxamide;
CAS Number	185106-16-5 ;
PubChem CID	5282338;
ChemSpider	4445505 ;
UNII	D42OWK5383;
KEGG	D08838 ;
ChEMBL	ChEMBL2107723 ;
Chemical and physical data
Formula	C21H30N4O5S
Molar mass	450.55 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C(Nc1nc(C(=O)NCCN(C(C)C)C(C)C)cs1)c2cc(OC)c(OC)cc2O;
	InChI InChI=1S/C21H30N4O5S/c1-12(2)25(13(3)4)8-7-22-20(28)15-11-31-21(23-15)24-19(27)14-9-17(29-5)18(30-6)10-16(14)26/h9-13,26H,7-8H2,1-6H3,(H,22,28)(H,23,24,27) ; Key:TWHZNAUBXFZMCA-UHFFFAOYSA-N ;
	(what is this?) (verify)

Acotiamide (brand name Acofide, codenamed YM-443 and Z-338) is a drug manufactured and approved in Japan for the treatment of postprandial fullness, upper abdominal bloating, and early satiation due to functional dyspepsia.[2] It acts as an acetylcholinesterase inhibitor. It is pending approval in the United States; ten clinical trials have been successfully completed.

References

"Acofide (acotiamide hydrochloride hydrate) Tablets Review Report" (PDF). Retrieved 29 December 2016.
Matsueda K, Hongo M, Tack J, Aoki H, Saito Y, Kato H (June 2010). "Clinical trial: dose-dependent therapeutic efficacy of acotiamide hydrochloride (Z-338) in patients with functional dyspepsia - 100 mg t.i.d. is an optimal dosage". Neurogastroenterology and Motility. 22 (6): 618–e173. doi:10.1111/j.1365-2982.2009.01449.x. PMID 20059698.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] "Acofide (acotiamide hydrochloride hydrate) Tablets Review Report" (PDF). Retrieved 29 December 2016.

[2] Matsueda K, Hongo M, Tack J, Aoki H, Saito Y, Kato H (June 2010). "Clinical trial: dose-dependent therapeutic efficacy of acotiamide hydrochloride (Z-338) in patients with functional dyspepsia - 100 mg t.i.d. is an optimal dosage". Neurogastroenterology and Motility. 22 (6): 618–e173. doi:10.1111/j.1365-2982.2009.01449.x. PMID 20059698.